Immunogenicity and vaccine effectiveness of COVID-19 vaccines in people on immunosuppressive therapies
This study demonstrates that while SARS-CoV-2 vaccine-induced antibody levels correlate with protection in immunosuppressed individuals, these patients exhibit lower vaccine effectiveness against infection and hospitalization than healthy controls at equivalent antibody levels, highlighting a disconnect between antibody titers and clinical protection in this high-risk population.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
When a vaccine works, it teaches the body to recognize a virus and build a shield of proteins called antibodies. For most people, the amount of these antibodies in the blood is a reliable sign of how well they are protected. If the levels are high, the person is likely safe from infection; if they are low, the protection is weak. This relationship has become a standard way for scientists and health officials to judge how well a vaccine is working. However, this rule was built on data from healthy people. A large group of individuals who take medicines to calm down their own overactive immune systems—people with conditions like cancer, multiple sclerosis, or severe arthritis—were often left out of the original studies. These patients are at higher risk of severe illness, yet it remained unclear if the same antibody rules applied to them. Does a low antibody level mean the same thing for a person on immunosuppressive therapy as it does for a healthy person? And does the type of medicine they take matter more than the disease they have?
A team of researchers set out to answer these questions by gathering data from dozens of studies involving people on immunosuppressive therapies who had received mRNA COVID-19 vaccines. They focused on measuring the binding antibodies, which are the proteins that stick to the virus, in patients with blood cancers, neurological disorders, rheumatic diseases, and other inflammatory conditions. The team compared these levels against those of healthy people and also looked at how well the vaccines actually prevented infection, hospitalization, and death in these groups. Their goal was to see if the amount of antibody produced could still predict protection when the immune system is being held back by medication.
The researchers found that the type of medicine a patient takes is far more important than the specific disease they have in determining how well their body responds to the vaccine. While the underlying condition played a role, the treatment itself drove the results. Patients treated with therapies that deplete B-cells, the immune cells responsible for making antibodies, or drugs that block a specific signaling molecule called S1P, showed the most dramatic drop in antibody production. These groups had antibody levels that were roughly fifty-five times and twenty-five times lower, respectively, than those of healthy people. Other treatments, such as those targeting inflammation with different mechanisms, caused much smaller reductions. Some patients on certain standard drugs for arthritis or bowel disease had antibody levels that were only slightly lower than healthy controls, suggesting their immune systems were still quite capable of responding.
The study then connected these antibody numbers to real-world outcomes. The researchers combined their antibody data with previous records of how well vaccines worked in preventing illness and hospitalization. They confirmed that, generally, higher antibody levels did correlate with better protection for these patients. However, a crucial difference emerged when they compared these patients to the general population. For any given level of antibodies, a person on immunosuppressive therapy was less protected than a healthy person with the same amount of antibodies. This suggests that the medicines these patients take do more than just lower antibody numbers; they may also weaken other parts of the immune defense that help keep the virus at bay. In other words, even if a patient manages to build up a certain amount of antibodies, their body might not use them as effectively as a healthy person's body would.
One interesting exception noted in the data involved a small group of patients with multiple sclerosis who were on B-cell depletion therapy. Despite having very low antibody levels, this group showed surprisingly high protection against hospitalization, performing better than the general population's expected results for that antibody level. However, the researchers cautioned that this was based on very limited data and could not be used to draw firm conclusions about why this happened. It remains possible that other factors, such as how carefully these patients avoid exposure to the virus, influenced the results. The study also highlighted that while vaccines are still beneficial for these patients, the protection they offer is not as strong as in the general public, even when antibody levels look similar.
Ultimately, the work provides a clearer picture of how different treatments affect vaccine responses. It suggests that doctors should consider the specific medication a patient is taking rather than just their diagnosis when assessing vaccine needs. The findings reinforce that while vaccines are essential for people on immunosuppressive therapies, the standard rules for interpreting antibody levels need to be adjusted for this group. A low antibody count in these patients is a strong warning sign, but even a moderate count might not offer the same safety net it would for someone without immune-suppressing medication. This distinction is vital for understanding the true level of risk these vulnerable populations face and for guiding future medical decisions.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.